Company news

Tvardi Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

March 13, 2023

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

March 5, 2023

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

February 20, 2023

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

February 7, 2023

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

January 16, 2023

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Cara Therapeutics Reports Third Quarter 2022 Financial Results

November 6, 2022

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

November 2, 2022

Cara Therapeutics to Present at Upcoming Investor Conferences

November 1, 2022

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

October 23, 2022

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

October 9, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

September 27, 2022

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

September 11, 2022

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

September 7, 2022

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

August 23, 2022

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

August 21, 2022

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

August 18, 2022

Cara Therapeutics Reports Second Quarter 2022 Financial Results

August 7, 2022

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 2, 2022

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

July 31, 2022

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

June 29, 2022

Cara Therapeutics Reports First Quarter 2022 Financial Results

May 8, 2022

Cara Therapeutics to Present at May Investor Conferences

May 2, 2022

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

April 28, 2022

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

April 27, 2022

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

April 4, 2022

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

April 3, 2022

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

March 27, 2022

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

March 7, 2022

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

February 27, 2022

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

February 21, 2022

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

February 17, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

January 9, 2022

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

December 19, 2021

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November 17, 2021

Cara Therapeutics Reports Third Quarter 2021 Financial Results

November 7, 2021

Cara Therapeutics Announces CEO Transition

November 2, 2021

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

October 31, 2021

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

October 3, 2021

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

September 28, 2021

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

September 23, 2021

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

August 23, 2021

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

August 22, 2021

Cara Therapeutics Reports Second Quarter 2021 Financial Results

August 8, 2021

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

August 1, 2021

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics

June 10, 2021

Cara Therapeutics Reports First Quarter 2021 Financial Results

May 9, 2021

← Newer news releases

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.